Portugal's Bial launches Ongentys for Parkinson´s disease in UK

Portugal’s largest drugmaker Bial says that its Ongentys (opicapone) has now been launched in the UK for the treatment of adult Parkinson´s disease patients with motor fluctuations.

Ongentys was authorized by the European Commission in June this year as an adjunctive therapy to preparations of levodopa/DOPA decarboxylase inhibitors (DDCIs) in adult patients with Parkinson’s disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations

“There is still an unmet medical need for effective new therapeutic options for Parkinson´s disease. Opicapone will provide clinicians in UK with a COMT inhibitor, with the convenience of once-daily dosing. It is an option when levodopa-treated patients need additional help to improve motor symptoms such as wearing off in Parkinson´s disease,” said Andrew Lees, Professor of Neurology at the National Hospital for Neurology and Neurosurgery, Queen Square, London and University College London.